Athena Capital Advisors LLC Purchases Shares of 11,050 Vascular Biogenics Ltd (VBLT)

Athena Capital Advisors LLC purchased a new position in shares of Vascular Biogenics Ltd (NASDAQ:VBLT) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 11,050 shares of the biopharmaceutical company’s stock, valued at approximately $25,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. RBF Capital LLC acquired a new position in shares of Vascular Biogenics in the fourth quarter valued at approximately $353,000. First Republic Investment Management Inc. grew its position in shares of Vascular Biogenics by 7.4% in the first quarter. First Republic Investment Management Inc. now owns 145,000 shares of the biopharmaceutical company’s stock valued at $220,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Menta Capital LLC acquired a new position in shares of Vascular Biogenics in the first quarter valued at approximately $35,000. 14.06% of the stock is currently owned by hedge funds and other institutional investors.

Vascular Biogenics stock opened at $1.25 on Friday. Vascular Biogenics Ltd has a 12 month low of $0.60 and a 12 month high of $3.10. The company has a debt-to-equity ratio of 0.05, a quick ratio of 10.83 and a current ratio of 8.35. The company has a market capitalization of $46.65 million, a PE ratio of -2.02 and a beta of -0.25.

Vascular Biogenics (NASDAQ:VBLT) last issued its quarterly earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The company had revenue of $0.22 million during the quarter, compared to the consensus estimate of $2.30 million. Vascular Biogenics had a negative net margin of 2,724.02% and a negative return on equity of 31.69%. On average, analysts anticipate that Vascular Biogenics Ltd will post -0.61 EPS for the current year.

Several equities analysts have recently commented on the company. Chardan Capital reaffirmed a “neutral” rating on shares of Vascular Biogenics in a research report on Wednesday, March 13th. Zacks Investment Research downgraded Vascular Biogenics from a “hold” rating to a “sell” rating in a research report on Thursday, March 21st. ValuEngine downgraded Vascular Biogenics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of Vascular Biogenics in a research report on Thursday.

TRADEMARK VIOLATION NOTICE: This article was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://sportsperspectives.com/2019/05/19/athena-capital-advisors-llc-purchases-shares-of-11050-vascular-biogenics-ltd-vblt.html.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Further Reading: What is cost of equity?

Institutional Ownership by Quarter for Vascular Biogenics (NASDAQ:VBLT)

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.